Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

Lung Cancer

Volumn 78, Issue 3, 2012, Pages 239-244

  Zappa, Francesco ^a   Droege, Cornelia ^b   Betticher, Daniel ^c   von Moos, Roger ^d   Bubendorf, Lukas ^b   Ochsenbein, Adrian ^e   Gautschi, Oliver ^e   Oppliger Leibundgut, Elisabeth ^e   Froesch, Patrizia ^a   Stahel, Rolf ^f   Hess, Thomas ^g   Rauch, Daniel ^d   Schmid, Petra ^h   Mayer, Michael ⁱ   Crowe, Susanne ⁱ   Brauchli, Peter ⁱ   Ribi, Karin ^j   Pless, Miklos ^g  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Hopital Cantonal de Fribourg   (Switzerland)

^d University Hospital Bern ^*  (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^h CANTONAL HOSPITAL AARAU   (Switzerland)

ⁱ SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^j IBCSG Coordinating Center Bern   (Switzerland)

more..

Author keywords

Bevacizumab; Erlotinib; First line regimen; Metastatic; Non squamous NSCLC; Translational research

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ERLOTINIB; GEMCITABINE;

ACNE; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; COUGHING; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRY SKIN; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERTENSION; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; PRURITUS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; QUALITY OF LIFE; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84868301289     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.08.017     Document Type: Article

References (30)

1. Schiller J.H., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
2. Socinski M.A. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res 2004, 10(12 (Pt 2)):4210s-4214s.
3. Pal S.K., Figlin R.A., Reckamp K. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther 2010, 9(7):1931-1944.
4. Manegold C. Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2008, 8(5):689-699.
5. Reck M., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27(8):1227-1234.
6. Sandler A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
7. Reck M., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21(9):1804-1809.
8. Crino L., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010, 11(8):733-740.
9. Shepherd F.A., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
10. D'Addario G., et al. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 2008, 19(4):739-745.
11. Mok T.S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
12. Rosell R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
13. van Cruijsen H., Giaccone G., Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2005, 117(6):883-888.
14. Herbst R.S., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23(11):2544-2555.
15. Therasse P., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
16. Hollen P.J., et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994, 73(8):2087-2098.
17. Hollen P.J., et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 1993, 29A(Suppl. 1):S51-S58.
18. Bernhard J., et al. Patients' estimation of overall treatment burden: why not ask the obvious?. J Clin Oncol 2002, 20(1):65-72.
19. Hollen P.J., Gralla R.J. Clinical vs Statistical Significance: Using the LCSS Quality of Life Instrument and Karnofsky Performance Status (KPS) to Approach the Problem in Patients with Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 2000, 19(Suppl.). (abstr 2510).
20. Scagliotti G.V., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
21. Cappuzzo F., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529.
22. Ciuleanu T., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440.
23. Fidias P.M., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(4):591-598.
24. Paz-Ares L., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012, 13(3):247-255.
25. Gridelli C., et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012.
26. Kim E.S., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372(9652):1809-1818.
27. Herbst R.S., Sandler A. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 2008, 13(11):1166-1176.
28. Dingemans A.M., et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol 2011, 22(3):559-566.
29. Thomas M., et al. Innovations: randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl.). abstr 7504.
30. Herbst R.S., et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377(9780):1846-1854.